Recombinant Human Von Willebrand Factor/vWF Protein ，His

Von Willebrand Factor (vWF) is a critical multimeric glycoprotein involved in hemostasis, serving as a bridge between platelets and the endothelial collagen during vascular injury. Deficiencies or dysfunctions in vWF lead to von Willebrand disease (vWD), a common hereditary bleeding disorder that affects platelet adhesion and blood clotting. The complexity of vWF structure, which exists in various multimeric forms, is crucial for its biological function and regulation. Researchers have focused on recombinant vWF proteins to better understand the pathophysiology of vWD and to develop therapeutic strategies. Advances in recombinant DNA technology have facilitated the production of these proteins, allowing for the exploration of their physiological properties, including their interaction with platelets and the extracellular matrix. Furthermore, therapeutic applications of recombinant vWF aim to provide effective treatments for patients with vWD, improving their quality of life and reducing bleeding complications. Ongoing studies are investigating the efficacy, dosage, and safety of these recombinant proteins, with the goal of creating more refined and patient-specific treatment options. The research on recombinant vWF not only enhances our understanding of hemostatic mechanisms but also holds promise for innovative therapies in bleeding disorders.